Gilead Sciences, Inc.

Institute of Organic Chemistry and Biochemistry of the As Cr, V.v.i.

Institute of Organic Chemistry and Biochemistry Ascr, V.v.i.

Yunfeng Eric Hu

Winston C Tse

John O Link

Jennifer R Zhang

Qi Liu

Randall Halcomb

Scott D Schroeder

Richard L Mackman

Petr Jansa

Carina E Cannizzaro

Steven S Bondy

Eric Lansdon

Chien-Hung Chou

Milan Dejmek

Ondrej Baszczynski

Petr Simon

Eda Y Canales

Gediminas J Brizgys

Roland D Saito

Chien-hung Chou

Michael Graupe

Darryl Kato

John R Somoza

Gediminas Brizgys

Kevin S Currie

Scott E Lazerwith

Lianhong Xu

Dmitry Koltun

Eric Q Parkhill

Jiayao Li

Samuel E Metobo

Ryan McFadden

Michael R Mish

Qiaoyin Wu

David Sperandio

Hai Yang

Gregory F Chin

Nathan D Shapiro

Evangelos Aktoudianakis

Tomas Cihlar

Xiaochun Han

Yafan Lu

Helen Yu

Michael O' Neil Hanrahan Clarke

Randall L Halcomb

Derek Dean Sloan

Jeffrey Patrick Murry

George Stepan

Tim Hansen

Eda Canales

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.

Quinazoline compounds

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating cancers.

Imidazopyrimidine derivatives

The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus. 

Compounds for the treatment of HIV

The present disclosure generally relates to compounds and pharmaceutical compositions which may be used in methods of treating a hepatitis B virus infection.

Compounds for the treatment of hepatitis B virus infection

Provided are compounds, compositions, combinations, kits, uses, and methods for treating HIV in a human being using such compounds or combinations with proteasome inhibitors.

Compounds and combinations for the treatment of HIV

Compounds of formula (I) or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus. 

Therapeutic compounds

Compounds of formula I: or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

Isoquinoline compounds

Compounds of formula I: or pharmaceutically acceptable salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

Growing community of inventors

San Mateo, CA, United States of America

Yunfeng Eric Hu